Phase II Study of Everolimus in Patients With Metastatic Colorectal Adenocarcinoma Previously Treated With Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens

PURPOSE: Dysregulation of the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is seen in 40–60% of colorectal cancer (CRC) patients. Everolimus, an oral inhibitor of mTOR, demonstrated efficacy in metastatic CRC (mCRC) patients in phase I studies. EXPERIMENTAL D...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Ng, Kimmie, Tabernero, Josep, Hwang, Jimmy, Bajetta, Emilio, Sharma, Sunil, Del Prete, Salvatore A., Arrowsmith, Edward R., Ryan, David P., Sedova, Michaela, Jin, Jin, Malek, Kamel, Fuchs, Charles S.
Format: Artigo
Langue:Inglês
Publié: 2013
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3725595/
https://ncbi.nlm.nih.gov/pubmed/23743569
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-0027
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires